IPGMER and SSKM Hospital

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Heart failure2 trials
• Atrial fibrillation1 trial
• Coronary artery disease1 trial
• Lung cancer1 trial
• Lupus (SLE)1 trial

Phase

• Phase 35 trials
• Phase 21 trial

Status

• Not yet recruiting2 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Completed1 trial

Lead sponsor

• Boehringer Ingelheim3 trials
• Janssen Research & Development, LLC2 trials
• SystImmune Inc.1 trial

Running trials

• Recruiting

  BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

  NCT07625644· Phase 3· SystImmune Inc.· Source

  Contact: Suparna Kanti Pal (principal investigator)

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure2 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source